CN103773880B - Application of substances for detecting rs6461563 site nucleotide in early evaluation of risk of schizophrenia - Google Patents
Application of substances for detecting rs6461563 site nucleotide in early evaluation of risk of schizophrenia Download PDFInfo
- Publication number
- CN103773880B CN103773880B CN201410044742.4A CN201410044742A CN103773880B CN 103773880 B CN103773880 B CN 103773880B CN 201410044742 A CN201410044742 A CN 201410044742A CN 103773880 B CN103773880 B CN 103773880B
- Authority
- CN
- China
- Prior art keywords
- sequence
- site
- sequence table
- probe
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
The invention discloses application of substances for detecting rs6461563 site nucleotide in early evaluation of risk of schizophrenia, and particularly relates to application of substances for detecting rs6461563 site nucleotide in early evaluation of risk of schizophrenia of children and adolescents. The invention has significant application value for preventing and controlling schizophrenia, especially schizophrenia of children and adolescents.
Description
Technical field
The material that the present invention relates to for detecting rs6461563 position nucleotide evaluates the application in schizophrenia risk in early days, and the material be specifically related to for detecting rs6461563 position nucleotide evaluates the application in children and adolescents schizophrenia risk in early days.
Background technology
Schizophrenia is the not bright mental disease of one group of cause of disease, many person between twenty and fifty slow or subacute onset, often show as the different syndrome of symptom clinically, relate to the inharmonious of many-sided obstacles such as sensory perception, thinking, emotion and behavior and cerebration, between individuality, symptom is widely different, even if same patient also may show different symptoms in different steps or stadium.
Schizoid clinical manifestation is as follows:
1, sensory perception obstacle
Can be there is multiple sensory perception obstacle in schizophrenia, the most outstanding sensory perception obstacle is illusion, comprise phonism, photis, olfactory hallucination, gustatory hallucination and tactile hallucination etc., and phonism is the most common.
2, the disturbance of thought
The disturbance of thought is schizoid core symptom, mainly comprises form of thought obstacle and content of thought obstacle.Form of thought obstacle for main manifestations, comprises the obstacle of thinking association active procedure (amount, speed and form), the thinking association aspect such as continuity and logicality with thinking associative process obstacle.Vain hope is the most common, most important content of thought obstacle.The vain hope the most often occurred has persecutory delusion, delusion of relation, delusion of influence, delusion of jealousy, the delusion of grandeur, non-descent delusion etc.According to estimates, persecutory delusion is there is up to the schizophreniac of 80%, persecutory delusion can show as sense of insecurity in various degree, offerd medicine as being monitored, being ostracised, worry or murdered, under vain hope impact, patient can make defence or Aggression, in addition, feeling of passivity is also comparatively outstanding with it at some patients, has an impact to the thinking of patient, emotion and behavior.
3, affective disorder
Apathy and emotional responses is inharmonious is the modal affective symptom of schizophreniac, and in addition, the affective symptom such as incoordination excitement, irritability, depression and anxiety are also more common.
4, will and behavior disorder
The hypobulia of most of patients even lacks, and show as movable minimizing, peel off and stay alone, behavior is passive, lack due enthusiasm and initiative, working and learning interest is gone down, is indifferent to future, to clearly not intending in the future, some patient may have some plans and intend, but seldom performs.
5, cognition dysfunction
In schizophreniac, the incidence of cognitive defect is high, and cognition dysfunction appears in about 85% patient, as information processing and selective attention, working memory, short-term memory and the cognitive defect such as study, n-back test.Certain dependency is there is between cognitive defect symptom and other psychotic symptoms, the cognitive defect symptom of patient as obvious in form of thought obstacle is more obvious, the cognitive defect symptom of the obvious patient of negative symptoms is more obvious, and cognitive defect may be relevant with the generation of some positive symptom etc.Cognitive defect may betide psychotic symptoms clear before (as prodromal stage), or sharply decline along with the appearance of psychotic symptoms, or extend along with the course of disease and progressively fail, tentatively think that Patients with Chronic Schizophrenia is more obvious than the cognitive defect of first episode schizophrenia.
Schizoid clinical classification is as follows:
1, intolerance style
This is a modal type in schizophrenia, with illusion, vainly hopes for main clinical manifestation.
2, hebephrenictype
In adolescence morbidity, with significant thinking, emotion and behavior disorder for main manifestations, typical performance is loosening of association, the split of thought, and emotion, behavior reaction are inmature, may with the illusion of fragment, vain hope; It is hyperfunction that some patients can show as instinctive activity, as appetite, sexual desire enhancing etc.This type patient first-episode age is low, and onset is anxious, and social function is obviously impaired, and general prognosis is not good.
3, catatonic type
Take tension syndrome as main manifestations, patient can show as catatonic sqtupor, waxy flexibility, mechanical words and deeds, and incoordination psychomotor excitement, impulsive action.General this type patient onset is comparatively anxious, and some patients is alleviated rapidly.
4, simple form
This type is mainly in morbidity in pubescence, and main manifestations is negative symptoms, shrinks back, flat affect or indifferent etc. as unsociable and eccentric.This type result for the treatment of is not good enough, and the decline of patient's social function is obvious, poor prognosis.
5, undifferentiated type
This type has the part feature of certain type above-mentioned, or has above-mentioned various Some features, but is difficult to be included into above-mentioned any type.
6, Residual-type
This type is the stage after schizophrenia acute phase, and main manifestations is the change of personality or the decline of social function.
External conventional Case definition comprises the International Classification of Diseases handbook ICD-10 of the classification of diseases of the U.S. and DSM DSM-IV-TR, WHO, and domestic conventional Case definition is Chinese Spirit Obstacles classification and Case definition CCMD-3.
Summary of the invention
The material that the object of this invention is to provide for detecting rs6461563 position nucleotide evaluates the application in schizophrenia risk in early days, and the material be specifically related to for detecting rs6461563 position nucleotide evaluates the application in children and adolescents schizophrenia risk in early days.
The invention provides the application of material in preparing product of the Nucleotide for detecting rs6461563 site; The function of described product suffers from schizoid risk for evaluating (particularly EARLY STAGE EVALUATION) or auxiliary evaluation (particularly early stage auxiliary evaluation) people to be measured.
Present invention also offers the application of material in preparing product of the Nucleotide for detecting rs6461563 site; The function of described product is for diagnosing whether (particularly early diagnosis) or auxiliary diagnosis (particularly early stage auxiliary diagnosis) patient to be measured is schizophreniac.
The present invention also protects a kind of product, the material containing the Nucleotide for detecting rs6461563 site; The function of described product is that EARLY STAGE EVALUATION (particularly EARLY STAGE EVALUATION) or auxiliary evaluation (particularly early stage auxiliary evaluation) people to be measured suffer from schizoid risk.Described product also can comprise the carrier recording following (a) or (b): if G allelotrope is carried in the rs6461563 site in the genomic dna of (a) people to be measured, it is higher that people to be measured suffers from schizoid risk; If G allelotrope is not carried in the rs6461563 site in the genomic dna of people to be measured, it is lower that people to be measured suffers from schizoid risk; If b the rs6461563 site in the genomic dna of () people to be measured is GG genotype or GT genotype, it is higher that people to be measured suffers from schizoid risk; If the rs6461563 site in the genomic dna of people to be measured is TT genotype, it is lower that people to be measured suffers from schizoid risk.
The present invention also protects a kind of product, the material containing the Nucleotide for detecting rs6461563 site; The function of described product is for diagnosing whether (particularly early diagnosis) or auxiliary diagnosis (particularly early stage auxiliary diagnosis) patient to be measured is schizophreniac.
Arbitrary described rs6461563 site specifically can be above: with the genomic dna of people to be measured for template, adopt special primer to increase obtain amplified production from 5 ' end the 44th Nucleotide; Described special primer forms the single strand dna shown in the sequence 2 by the single strand dna shown in the sequence 1 of sequence table and sequence table.
Above arbitrary described " for detecting the material of the Nucleotide in rs6461563 site " special primer, probe first and probe second are made up of; Described special primer forms the single strand dna shown in the sequence 2 by the single strand dna shown in the sequence 1 of sequence table and sequence table; Described probe first is as shown in the sequence 3 of sequence table; Described probe second is as shown in the sequence 4 of sequence table.
Arbitrary described people to be measured specifically can be children to be measured or teenager to be measured above.
The present invention also protects a kind of test kit of the Nucleotide for detecting rs6461563 site, is made up of, probe first and probe second special primer; Described special primer forms the single strand dna shown in the sequence 2 by the single strand dna shown in the sequence 1 of sequence table and sequence table; Described probe first is as shown in the sequence 3 of sequence table; Described probe second is as shown in the sequence 4 of sequence table.Described rs6461563 site specifically can be: with the genomic dna of people to be measured for template, adopt described special primer to increase obtain amplified production from 5 ' end the 44th Nucleotide.
The present invention also protects rs6461563 site developing or designing as mark or preparing the application in the product detecting schizoid risk.Described rs6461563 site specifically can be: with the genomic dna of people to be measured for template, adopt described special primer to increase obtain amplified production from 5 ' end the 44th Nucleotide.
The present invention, for the schizoid prevention and control of schizoid prevention and control, particularly Children and teenager, has great using value.
Embodiment
Following embodiment is convenient to understand the present invention better, but does not limit the present invention.Experimental technique in following embodiment, if no special instructions, is ordinary method.Test materials used in following embodiment, if no special instructions, is and purchases available from routine biochemistry reagent shop.Quantitative test in following examples, all arranges and repeats experiment for three times, results averaged.SNP site and mononucleotide polymorphism site, each rs site is certain concrete SNP site.Rs6461563 site is positioned at No. 7 karyomit(e)s (take human gene group DNA as template, the nucleotide sequence adopting single strand dna shown in the sequence 2 of single strand dna and sequence table shown in the sequence 1 of sequence table to carry out the product that pcr amplification obtains specifically can as shown in the sequence 5 of sequence table).Schizoid Case definition is Chinese Spirit Obstacles classification and Case definition CCMD-3, and healthy person is the people getting rid of relative disease by above-mentioned standard diagnostics.
The association analysis of embodiment 1, rs6461563 position nucleotide and schizophrenia risk
For carrying out the crowd of association analysis: the schizophreniac 1127 that makes a definite diagnosis of hospital, Serious depression patient 942, healthy person 1164, is the volunteer of informed consent, is Han nationality.
1, get the blood of each individuality respectively, extract genomic dna.
2, the genomic dna extracted with step 1, for template, adopts TaqMan real-time fluorescence PCR qualification rs6461563 position nucleotide.
Upstream primer (sequence 1 of sequence table): 5'-CAGCACACGGTCTTAGGCTTT-3';
Downstream primer (sequence 2 of sequence table): 5'-CAGAGGAAATCCCAGACATATCACT-3';
TaqMan probe 1(5' → 3', its nucleotides sequence is classified as the sequence 3 of sequence table, for detecting allelotrope G):
FAM-TTCTCACAAGCCGCCT-MGB；
TaqMan probe 2(5' → 3', its nucleotides sequence is classified as the sequence 4 of sequence table, for detecting allelotrope T):
VIC-TTCTCACAAGCCTCCT-MGB。
VIC and FAM is fluorophor.MGB is fluorescent quenching group.
The results are shown in Table 1.
Table 1 detected result
After multiple hypothesis test corrects, find the gene frequency distribution in rs6461563 site relevant to schizophrenia (Pallele=0.0033 corrects rear Pallele=0.0264).The G allelotrope in rs6461563 site is more common in schizophrenia crowd, may increase schizoid risk.This result illustrates, SP4 gene may be the tumor susceptibility gene of schizophreniac, and rs6461563 site is associated with schizophrenia, may be the risk site of this disease, or be associated with the risk site of this disease.By carrying out gene type to rs6461563 site and can assess the schizophrenia risk of test individual or whether auxiliary diagnosis test individual being schizophreniac.
Because children and adolescents is schizoid group of people at high risk, the present invention has outstanding value for evaluation children and adolescents schizophrenia risk.
Claims (9)
1., for detecting the application of material in preparing product of the Nucleotide in rs6461563 site, the function of described product is that evaluation or auxiliary evaluation people to be measured suffer from schizoid risk.
2. for detecting the application of material in preparing product of the Nucleotide in rs6461563 site; Whether the function of described product is diagnosis or auxiliary diagnosis patient to be measured is schizophreniac.
3. apply as claimed in claim 1 or 2, it is characterized in that: described rs6461563 site is: with the genomic dna of people to be measured for template, adopt special primer to increase obtain amplified production from 5 ' end the 44th Nucleotide, described special primer forms the single strand dna shown in the sequence 2 by the single strand dna shown in the sequence 1 of sequence table and sequence table.
4. apply as claimed in claim 1 or 2, it is characterized in that: described " for detecting the material of the Nucleotide in rs6461563 site " is made up of, probe first and probe second special primer, described special primer forms the single strand dna shown in the sequence 2 by the single strand dna shown in the sequence 1 of sequence table and sequence table, described probe first is as shown in the sequence 3 of sequence table, and described probe second is as shown in the sequence 4 of sequence table.
5. the material containing the Nucleotide for detecting rs6461563 site, the function of described material is that EARLY STAGE EVALUATION or auxiliary evaluation people to be measured suffer from schizoid risk.
6. the material containing the Nucleotide for detecting rs6461563 site, whether the function of described material is diagnosis or auxiliary diagnosis patient to be measured is schizophreniac.
7. the material as described in claim 5 or 6, it is characterized in that: described rs6461563 site is: with the genomic dna of people to be measured for template, adopt special primer to increase obtain amplified production from 5 ' end the 44th Nucleotide, described special primer forms the single strand dna shown in the sequence 2 by the single strand dna shown in the sequence 1 of sequence table and sequence table.
8. the material as described in claim 5 or 6, it is characterized in that: described material is made up of, probe first and probe second special primer, described special primer forms the single strand dna shown in the sequence 2 by the single strand dna shown in the sequence 1 of sequence table and sequence table, and described probe first is as shown in the sequence 3 of sequence table; Described probe second is as shown in the sequence 4 of sequence table.
9. one kind for detecting the test kit of the Nucleotide in rs6461563 site, special primer, probe first and probe second are made up of, described special primer forms the single strand dna shown in the sequence 2 by the single strand dna shown in the sequence 1 of sequence table and sequence table, and described probe first is as shown in the sequence 3 of sequence table; Described probe second is as shown in the sequence 4 of sequence table.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410044742.4A CN103773880B (en) | 2014-02-07 | 2014-02-07 | Application of substances for detecting rs6461563 site nucleotide in early evaluation of risk of schizophrenia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410044742.4A CN103773880B (en) | 2014-02-07 | 2014-02-07 | Application of substances for detecting rs6461563 site nucleotide in early evaluation of risk of schizophrenia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103773880A CN103773880A (en) | 2014-05-07 |
| CN103773880B true CN103773880B (en) | 2015-07-15 |
Family
ID=50566636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410044742.4A Expired - Fee Related CN103773880B (en) | 2014-02-07 | 2014-02-07 | Application of substances for detecting rs6461563 site nucleotide in early evaluation of risk of schizophrenia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103773880B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1635142A (en) * | 2003-12-26 | 2005-07-06 | 中国医学科学院基础医学研究所 | Reagent kit for forecasting susceptibility of intolerance type dementia preaecox and primer used thereby |
| CN102146479A (en) * | 2011-04-15 | 2011-08-10 | 上海交通大学 | Primers and probes for detecting genes associated with schizophrenia, bipolar affective disorders and major depression and kits and preparation methods thereof |
-
2014
- 2014-02-07 CN CN201410044742.4A patent/CN103773880B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1635142A (en) * | 2003-12-26 | 2005-07-06 | 中国医学科学院基础医学研究所 | Reagent kit for forecasting susceptibility of intolerance type dementia preaecox and primer used thereby |
| CN102146479A (en) * | 2011-04-15 | 2011-08-10 | 上海交通大学 | Primers and probes for detecting genes associated with schizophrenia, bipolar affective disorders and major depression and kits and preparation methods thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103773880A (en) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Epel et al. | Stress, telomeres, and psychopathology: toward a deeper understanding of a triad of early aging | |
| Carlberg et al. | Brain-derived neurotrophic factor (BDNF)—Epigenetic regulation in unipolar and bipolar affective disorder | |
| Zhou et al. | Global long non-coding RNA expression in the rostral anterior cingulate cortex of depressed suicides | |
| Breitenstein et al. | Are there meaningful biomarkers of treatment response for depression? | |
| CN108291259A (en) | Introgression is predicted using the genome and clinical risk evaluation of combination | |
| Piyathilake et al. | A lower degree of PBMC L1 methylation is associated with excess body weight and higher HOMA-IR in the presence of lower concentrations of plasma folate | |
| Guo et al. | The vasculome of the mouse brain | |
| Akasheva et al. | Age-related left ventricular changes and their association with leukocyte telomere length in healthy people | |
| Kumar et al. | Identification of factors associated with treatment refractoriness of oral lesions in pemphigus vulgaris | |
| Chiappelli et al. | Salivary biomarkers in psychobiological medicine | |
| Friedrich et al. | Complexity of infection and genetic diversity in Cambodian Plasmodium vivax | |
| Christensen et al. | Molecular profiling of the lateral habenula in a rat model of depression | |
| Pepin et al. | The human aortic endothelium undergoes dose-dependent DNA methylation in response to transient hyperglycemia | |
| Fiori et al. | Investigating epigenetic consequences of early-life adversity: Some methodological considerations | |
| Ludwig et al. | Influence of CRHR1 polymorphisms and childhood abuse on suicide attempts in affective disorders: a GxE approach | |
| Yee et al. | Peripheral blood gene expression of acute phase proteins in people with first episode psychosis | |
| Cesca et al. | Evaluating the SERCA2 and VEGF mRNAs as potential molecular biomarkers of the onset and progression in Huntington’s disease | |
| Yao et al. | Blocker displacement amplification mediated PCR based screen-printed carbon electrode biosensor and lateral flow strip strategy for CYP2C19* 2 genotyping | |
| Bly et al. | P-glycoprotein (PGP) polymorphisms and sexual dysfunction in female patients with depression and SSRI-associated sexual side effects | |
| Massey et al. | Preliminary evidence for the interaction of the oxytocin receptor gene (oxtr) and face processing in differentiating prenatal smoking patterns | |
| Sun et al. | Identification of global mRNA expression profiles and comprehensive bioinformatic analyses of abnormally expressed genes in cholestatic liver disease | |
| Disner et al. | 5-HTTLPR, HTR1A, and HTR2A cumulative genetic score interacts with mood reactivity to predict mood-congruent gaze bias | |
| CN103773880B (en) | Application of substances for detecting rs6461563 site nucleotide in early evaluation of risk of schizophrenia | |
| Gao et al. | Expression levels of vascular endothelial cell growth factor and microRNA‑210 are increased in medulloblastoma and metastatic medulloblastoma | |
| Yucesoy et al. | Genetic basis of irritant susceptibility in health care workers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150715 Termination date: 20180207 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |